» Articles » PMID: 1281290

Beta-Amyloid Peptide in Vitro Toxicity: Lot-to-lot Variability

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 1992 Sep 1
PMID 1281290
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

beta A4 peptide (beta AP) accumulates in amyloid plaques of Alzheimer's disease and may contribute to neuronal degeneration. Conflicting observations have been reported regarding the direct in vitro and in vivo neurotoxicity of beta AP. We have assessed in vitro beta AP toxicity in high density primary rat hippocampal cultures and found marked lot-to-lot differences in the neurotoxic properties of beta AP. One lot of beta AP from a commercial supplier resulted in significant direct neurotoxicity at 10 microM, while 2 other lots from the same supplier were essentially nontoxic. Three additional lots of beta AP from unrelated sources were also nontoxic at 10 microM. Initial biochemical characterization has not yet revealed any marked differences among the various lots of beta AP. Low levels of endotoxin (ca., 1 EU/ml) were detected in several beta AP preparations but did not correlate with neurotoxicity. Our observation that lot-to-lot variability of beta AP occurred even under identical in vitro culture conditions may account for part of the present controversy in this area.

Citing Articles

Concentration-dependent effects of mercury and lead on Aβ42: possible implications for Alzheimer's disease.

Meleleo D, Notarachille G, Mangini V, Arnesano F Eur Biophys J. 2019; 48(2):173-187.

PMID: 30603762 DOI: 10.1007/s00249-018-1344-9.


Amyloid beta-peptide worsens cognitive impairment following cerebral ischemia-reperfusion injury.

Song B, Ao Q, Niu Y, Shen Q, Zuo H, Zhang X Neural Regen Res. 2014; 8(26):2449-57.

PMID: 25206555 PMC: 4146113. DOI: 10.3969/j.issn.1673-5374.2013.26.006.


Change of dynamics of raft-model membrane induced by amyloid-β protein binding.

Hirai M, Kimura R, Takeuchi K, Sugiyama M, Kasahara K, Ohta N Eur Phys J E Soft Matter. 2013; 36(7):74.

PMID: 23852578 DOI: 10.1140/epje/i2013-13074-3.


Targets for AD treatment: conflicting messages from γ-secretase inhibitors.

Sambamurti K, Greig N, Utsuki T, Barnwell E, Sharma E, Mazell C J Neurochem. 2011; 117(3):359-74.

PMID: 21320126 PMC: 3076515. DOI: 10.1111/j.1471-4159.2011.07213.x.


Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments.

Li H, Monien B, Lomakin A, Zemel R, Fradinger E, Tan M Biochemistry. 2010; 49(30):6358-64.

PMID: 20568734 PMC: 2912417. DOI: 10.1021/bi100773g.